Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.24
(-5.4%)
USD 1.24
(-5.4%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 31.24 Million USD | 5.03% |
| 2022 | 29.75 Million USD | 340.05% |
| 2021 | 6.76 Million USD | 4.3% |
| 2020 | 6.48 Million USD | 53.35% |
| 2019 | 4.22 Million USD | -31.28% |
| 2018 | 6.15 Million USD | 265.48% |
| 2017 | 1.68 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.39 Million USD | -86.35% |
| 2024 Q2 | 2.76 Million USD | 15.35% |
| 2023 Q3 | 9.28 Million USD | 396.63% |
| 2023 Q1 | 2.52 Million USD | -67.39% |
| 2023 FY | 31.24 Million USD | 5.03% |
| 2023 Q2 | 1.86 Million USD | -26.07% |
| 2023 Q4 | 17.57 Million USD | 89.29% |
| 2022 Q2 | 1.52 Million USD | 5.16% |
| 2022 FY | 29.75 Million USD | 340.05% |
| 2022 Q4 | 7.75 Million USD | -59.23% |
| 2022 Q3 | 19.01 Million USD | 1144.63% |
| 2022 Q1 | 1.45 Million USD | -3.2% |
| 2021 Q2 | 1.82 Million USD | 2.64% |
| 2021 Q1 | 1.77 Million USD | 12.47% |
| 2021 Q3 | 1.65 Million USD | -9.05% |
| 2021 Q4 | 1.5 Million USD | -9.52% |
| 2021 FY | 6.76 Million USD | 4.3% |
| 2020 Q1 | 1.4 Million USD | 28.49% |
| 2020 FY | 6.48 Million USD | 53.35% |
| 2020 Q2 | 2.04 Million USD | 45.42% |
| 2020 Q3 | 1.44 Million USD | -29.18% |
| 2020 Q4 | 1.58 Million USD | 9.04% |
| 2019 Q3 | 983 Thousand USD | 10.95% |
| 2019 Q1 | 1.26 Million USD | -28.72% |
| 2019 FY | 4.22 Million USD | -31.28% |
| 2019 Q4 | 1.09 Million USD | 11.39% |
| 2019 Q2 | 886 Thousand USD | -29.85% |
| 2018 Q4 | 1.77 Million USD | 58.5% |
| 2018 FY | 6.15 Million USD | 265.48% |
| 2018 Q3 | 1.11 Million USD | -47.83% |
| 2018 Q1 | 1.11 Million USD | 11.91% |
| 2018 Q2 | 2.14 Million USD | 91.68% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | 684 Thousand USD | 0.0% |
| 2017 Q4 | 999 Thousand USD | 46.05% |
| 2017 FY | 1.68 Million USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -97.242% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -16.501% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 92.175% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -264.505% |
| bluebird bio, Inc. | 29.49 Million USD | -5.94% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -49.032% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | 78.12 Million USD | 60.0% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.791% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 99.175% |
| Myriad Genetics, Inc. | 678.4 Million USD | 95.394% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 98.344% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 94.856% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.979% |
| Waters Corporation | 2.95 Billion USD | 98.943% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.927% |
| Biogen Inc. | 9.83 Billion USD | 99.682% |
| Nektar Therapeutics | 90.12 Million USD | 65.326% |
| Perrigo Company plc | 4.65 Billion USD | 99.329% |
| Dynavax Technologies Corporation | 232.28 Million USD | 86.547% |
| Illumina, Inc. | 4.5 Billion USD | 99.306% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -2528.175% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 75.403% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 98.708% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 82.268% |
| Evolus, Inc. | 202.08 Million USD | 84.537% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.762% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 73.139% |
| FibroGen, Inc. | 147.75 Million USD | 78.85% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 99.543% |
| OPKO Health, Inc. | 863.49 Million USD | 96.381% |
| Homology Medicines, Inc. | -6.65 Million USD | 569.839% |
| Geron Corporation | 237 Thousand USD | -13085.232% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 98.291% |
| Exelixis, Inc. | 1.83 Billion USD | 98.293% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 13.855% |
| Zoetis Inc. | 8.54 Billion USD | 99.634% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 88.452% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -792.829% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.683% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 96.033% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 97.487% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 93.522% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 96.232% |
| Blueprint Medicines Corporation | 249.38 Million USD | 87.469% |
| Insmed Incorporated | 305.2 Million USD | 89.761% |
| TG Therapeutics, Inc. | 233.66 Million USD | 86.626% |
| Incyte Corporation | 3.69 Billion USD | 99.154% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 97.022% |